BlackRock-Backed Swedish Fintech Startup Keeps IPO Plans At Bay Despite 51% Jump In Profit: Here’s Why
The CEO emphasized the need for more time to demonstrate the value of Trustly's open banking technology to investors.
UiPath Down 30% On Thursday – What’s Going On?
UiPath, Inc. (NYSE:PATH) shares are slumping in the premarket session on Thursday after ending yesterday’s run on a dull note.
Salesforce Plummets 16% Pre-Market Amid First Single-Digit Growth Projections In Two Decades
This marks the first time since 2006 that Salesforce missed its revenue target, based on LSEG data.
‘Fair Chance’ Elon Musk Will Leave Tesla If Shareholders Vote Against Compensation Package, Warns Gary Black
Black's comment was in response to the news that Marcie Frost, CEO of CalPERS, would vote against Musk's compensation package, despite having supported it in 2018.
Google Pledges $2B For Data Centre And Cloud Services In Malaysia
The data and cloud centers will be positioned in the Elmina Business Park, in central Selangor state, owned by Sime Darby Property.
Activist Investor Nelson Peltz Sells Entire Disney Stake For $1B After Losing Proxy Battle
Peltz has been critical of Disney's governance, particularly its streaming strategy and CEO succession plan.
Avidity Biosciences To Present Preliminary Data From Phase 1/2 FORTITUDE Trial Of AOC 1020 In People Living With Facioscapulohumeral Muscular Dystrophy At The 31st Annual FSHD Society International Research Congress
Jeffrey M. Statland, M.D., Professor of Neurology, University of Kansas Medical Center, and FORTITUDE trial investigator, will join Avidity management to present data from FORTITUDE™Avidity to host Volume 9 of
BridgeBio Pharma Announces Results Of Five New Analyses Of Clinical Endpoints From Phase 3 ATTRibute-CM Study of Acoramidis In ATTR-CM At ISA
- Acoramidis treatment resulted in increased serum transthyretin (TTR) levels by Day 28 that were sustained and were correlated with a reduced risk of all-cause mortality (ACM), cardiovascular mortality (CVM), and
GlycoMimetics To Host Leader Event To Review Results From Pivotal Phase 3 Study Of Uproleselan In Relapsed/Refractory Acute Myeloid Leukemia On June 4, 2024
GlycoMimetics, Inc. (NASDAQ:GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that it will host a key opinion
Is DraftKings Stock A Buy After Illinois Gambling Tax Hike?
DraftKings faces tax hike in Illinois, but analysts maintain bullish outlook with 56.49% upside. Bearish technical signals, but potential buy-the-dip opportunity for investors.